Less Ads, More Data, More Tools Register for FREE

Pin to quick picksARIX.L Regulatory News (ARIX)

  • There is currently no data for ARIX

Closed Period Notification

25 Feb 2022 17:30

RNS Number : 9131C
Arix Bioscience Plc
25 February 2022
 

25 February 2022

 

Arix Bioscience Plc (the "Company")

 

Closed Period Notification

 

In accordance with the provisions of the UK Market Abuse Regulation ("UK MAR"), the Company announces that it has today entered into a closed period which will remain in place until the Company publishes its annual financial results for the year ended 31 December 2021, with an expected publication date of early April, to be confirmed.

 

The Company confirms that it is satisfied that all inside information which the Directors and the Company may have had to the date of this announcement has been notified to a Regulatory Information Service. Accordingly, the Company is not prohibited from dealing in its own securities during this closed period. In the event that the Directors and the Company come into possession of any further insider information during the closed period, this will be notified to a Regulatory Information Service in accordance with UK MAR.

 

 

For and on behalf of the Company,

Deirdre Quinn

Derringtons Limited, Company Secretary

 

Enquiries: +44 (0) 20 8819 6486

Companysecretary@derringtons.com 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCMZGZZKKNGZZM
Date   Source Headline
16th Mar 20237:01 amEQSUnaudited NAV for February 2023
14th Feb 20236:19 pmEQSPortfolio company Disc Medicine announces $62.5 million financing
6th Feb 20236:00 pmEQSDirector/PDMR Shareholding
6th Feb 20235:00 pmEQSDirector/PDMR Shareholding
6th Feb 20238:00 amEQSUnaudited NAV for January 2023
6th Feb 20237:00 amEQSUnaudited NAV for January 2023
30th Jan 20238:00 amEQSUnaudited NAV for December 2022
30th Jan 20237:00 amEQSUnaudited NAV for December 2022
26th Jan 20238:00 amEQSBoard Change
26th Jan 20237:00 amEQSBoard Change
5th Jan 20235:20 pmEQSPortfolio company Twelve Bio to be acquired alongside $85 million financing of Ensoma
5th Jan 20234:21 pmEQSPortfolio company Twelve Bio to be acquired alongside $85 million financing of Ensoma
30th Dec 20228:01 amEQSPortfolio Company Disc Medicine Completes Merger with Gemini Therapeutics
30th Dec 20227:01 amEQSPortfolio Company Disc Medicine Completes Merger with Gemini Therapeutics
12th Dec 20228:00 amEQSUnaudited NAV for November 2022
12th Dec 20227:01 amEQSUnaudited NAV for November 2022
6th Dec 20228:00 amEQSArix to Present at Mello Investment Trusts & Funds
6th Dec 20227:00 amEQSArix to Present at Mello Investment Trusts & Funds
1st Dec 20227:45 amRNSDirector/PDMR Shareholding
9th Nov 20228:00 amEQSUnaudited NAV for October 2022
9th Nov 20227:00 amEQSUnaudited NAV for October 2022
28th Oct 20227:00 amEQSDirector/PDMR Shareholding
28th Oct 20227:00 amEQSDirector/PDMR Shareholding
20th Oct 20224:30 pmEQSHolding(s) in Company
20th Oct 20224:30 pmEQSHolding(s) in Company
14th Oct 20227:00 amEQSPortfolio Company Imara Announces Merger Agreement with Enliven Therapeutics
14th Oct 20227:00 amEQSPortfolio Company Imara Announces Merger Agreement with Enliven Therapeutics
11th Oct 20227:00 amEQSUnaudited NAV for September 2022
11th Oct 20227:00 amEQSUnaudited NAV for September 2022
5th Oct 20227:00 amEQSDirector/PDMR Shareholding
5th Oct 20227:00 amEQSDirector/PDMR Shareholding
3rd Oct 20224:32 pmEQSArix Portfolio Company Aura Biosciences Presents Interim Phase 2 Data Highlighting Belzupacap Sarotalocan (AU-011) Suprachoroidal Efficacy and Safety at AAO 2022
3rd Oct 20224:31 pmEQSArix Portfolio Company Aura Biosciences Presents Interim Phase 2 Data Highlighting Belzupacap Sarotalocan (AU-011) Suprachoroidal Efficacy and Safety at AAO 2022
15th Sep 20227:01 amEQSUnaudited NAV for August 2022
15th Sep 20227:00 amEQSUnaudited NAV for August 2022
12th Aug 20227:00 amEQSUnaudited NAV for July 2022
12th Aug 20227:00 amEQSUnaudited NAV for July 2022
10th Aug 20226:05 pmEQSArtios initiates Phase 2 study of Polθ Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer
10th Aug 20226:05 pmEQSArtios initiates Phase 2 study of Polθ Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer
10th Aug 20225:46 pmEQSPortfolio Company Disc Medicine Enters Definitive Merger Agreement with Gemini Therapeutics
10th Aug 20225:46 pmEQSPortfolio Company Disc Medicine Enters Definitive Merger Agreement with Gemini Therapeutics
10th Aug 20227:01 amEQSInterim Results for the Six Months Ended 30 June 2022
10th Aug 20227:01 amEQSArix Bioscience plc Announces Changes to Board of Directors
10th Aug 20227:01 amEQSArix Bioscience plc Announces Changes to Board of Directors
10th Aug 20227:00 amEQSInterim Results for the Six Months Ended 30 June 2022
3rd Aug 20227:00 amEQSNotice of Results & Investor Presentation
3rd Aug 20227:00 amEQSNotice of Results & Investor Presentation
22nd Jul 20227:00 amEQSUnaudited NAV for June 2022
22nd Jul 20227:00 amEQSUnaudited NAV for June 2022
22nd Jun 20224:45 pmEQSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.